Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Dr. Howard Weintraub MD

Clinical Director, NEW YORK UNIVERSITY (INC)

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation and treatment of patients prior to noncardiac surgery. He has also authored several articles on endothelial function and participated in clinical trials for treatment of lipid disorders. Dr. Weintraub has been named to the editorial board of Cardiology Review. He is one of the senior faculty in Vascular Biology Working Group and the Coalition for the Advancement of Cardiovascular Health, and is also a consultant to several pharmaceutical companies. (This is me - Update Profile)


Employment History

2004 - Unspecified
Clinical Director, NEW YORK UNIVERSITY (INC)

GLG NewsSM Analyses by Howard Weintraub(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Another piece of good news for a very good drug

November 8, 2007

Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com

By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level of BNP. This has not been as successful in patients without myocardial ischemia, but in those with ischemia the shortness of breath and associated chest discomfort has been helped in many. Including the most recent patient with a severe ischemic cardiomyopathy who has responded very very well with a significant increase in his functional capacity. Hopefully this news along with the safety from MERLIN and the A1C data and reduction in arrhythmias in that study will awaken docs to the benefits of Ranexa.  

Even more benefit.

November 8, 2007

Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com

The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.

This one may hurt.

June 15, 2007

FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com

It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in the near and mid-term future. This does not bode well for Sanofi, who will not have to regroup and pray for success with son of Amiodarone.

This one may hurt.

June 15, 2007

FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com

It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone mess (with Baychol and Vioxx undertones). This is going to create a real challenge for Sanofi and make them pray for succes with the "son of amiodarone".

Leading institutions connect with Howard Weintraub through GLG

GLG Live Meetings with Howard Weintraub(?)

Howard Weintraub has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare